MYMX Stock UPDATES Mymetics Corp (MYMX) 0.0322 10/22/2014 23

New Post Public Reply Private Reply Replies (0) Message Board

Oct 23, 2014 at 12:20 AM

Mymetics Corp (MYMX) 0.0322 $MYMX

Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute
Thomson Reuters ONE - Mon Sep 29, 6:03PM CDT
Mymetics Corporation and Texas Biomedical Research Institute / Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Mymetics Signs Agreement to Manufacture Virosome based HER-Vaxx Cancer Immunotherapy
Marketwire - Tue Jul 15, 7:00PM CDT
Mymetics (OTCBB: MYMX) announced today that it has signed an exclusive agreement with Imugene (ASX: IMU), an Australian based biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015.

Mymetics Strengthens Virosome Vaccine Platform
Marketwire - Mon Mar 10, 7:48AM CDT
Mymetics (OTCBB: MYMX) announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.

New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
SGYP: 2.72 (-0.13), CVM: 0.67 (-0.02), GSK: 44.41 (+0.78), SVA: 5.30 (-0.04), AGEN: 3.00 (unch), VICL: 1.18 (-0.02), FLML: 12.68 (-0.32), MRK: 55.51 (+0.38), NVS: 88.20 (-0.41)

OTC Signal Daily Stock Watch - Mymetics Corporation (OTCQB: MYMX)
WorldStockWire - Tue Sep 03, 7:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013
M2 - Tue Aug 13, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tl6fwn/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Syncytial Virus (RSV) Infections. - A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - Ablynx - Alios BioPharma, Inc. - Alnylam Pharmaceuticals, Inc - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Bavarian Nordic A/S - Celltrion, Inc. - Crucell N.V. - DBV Technologies - Functional Genetics, Inc. - GenVec, Inc. - Gilead Sciences, Inc. - iBio, Inc. - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Kineta, Inc. - LigoCyte Pharmaceuticals, Inc. - MedImmune LLC - Merus B.V. - MicroDose Therapeutx, Inc. - Mucosis B.V. - Mymetics Corporation - NanoBio Corporation - Novavax, Inc. - Okairos - Panacea Biotec Limited - Pevion Biotech Ltd - REPLICor Inc. - Romark Laboratories, L.C. - SelectX Pharmaceuticals, Inc. - Sirnaomics, Inc. - Spider Biotech S.r.l. - Symphogen A/S - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/tl...espiratory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 101.22 (+0.86), GILD: 106.09 (-0.58), NVAX: 4.85 (-0.14), IBIO: 1.77 (+0.03)

HIV / AIDS - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for HIV/AIDS
M2 - Wed Aug 07, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8df3d/hiv__aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. HIV / AIDS - Pipeline Review. Scope - A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Achillion Pharmaceuticals, Inc. Boehringer Ingelheim GmbH CONRAD Cellectis S.A. Esteve Group F. Hoffmann-La Roche Ltd. GeneCure LLC GlaxoSmithKline plc Heat Biologics, Inc. iCo Therapeutics Inc. ImQuest Life Sciences Johnson & Johnson Kainos Medicine, Inc. Koronis Pharmaceuticals, Inc. Laila Pharmaceuticals Pvt. Ltd. Medivir AB Merck & Co., Inc. Mymetics Corporation Novartis AG OyaGen Inc. PTC Therapeutics, Inc. Pfizer Inc. Pharmsynthez Sanofi-Aventis SuperGen, Inc. TVAX Biomedical, LLC Transgene Biotek Ltd United Biomedical, Inc. Viral Genetics, Inc. Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/d8df3d/hiv__aids About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HTBX: 6.06 (-0.47), ACHN: 11.06 (-0.37), PFE: 28.30 (+0.02), MRK: 55.51 (+0.38), PTCT: 36.97 (-0.93), GSK: 44.41 (+0.78), NVS: 88.20 (-0.41)

Data Published in PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity
Marketwire - Thu Feb 21, 1:31AM CST
Results from a randomized study published in PLOS ONE(1) today demonstrate that Mymetic' innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation (OTCBB: MYMX) is a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Frederick Foundation Welcomes New Leaders for Growth

Stirring the Philanthropic Pot in Frederick Moving pieces around the community chessboard once again, the Community Foundation of Frederick County brings in fresh minds—and the stakes have never been higher for these charitable endeavors. They've just put RaeAnn E. Butler at the helm, an established presence who’s now the primary captain steering this ship. Come...

Milton Hershey School's New Project: Founders Grove Launches

Breaking New Ground with Founders Grove It’s not every day a community gets a new lease on life through bricks and mortar, but Milton Hershey School (MHS) just did exactly that. They've broken ground on Founders Grove, a piece of the Hershey West End development puzzle that reflects both history and future potential. This isn’t just another housing project—this...

Tiana Marbuery Joins ALTA Division at Partner

Tiana Marbuery Dives In at Partner Forget flashy office parties and buzzword bingo. Today’s gig's all about substance. Partner Engineering and Science, Inc. just snagged themselves a heavy-hitter with Tiana Marbuery joining the ranks as Technical Director in their ALTA Division. This ain't a small fry deal—Marbuery's packing over eight years of hard-earned chops in...

SAGA Metals Enters Decision-Making Circles in Canada

Stepping into the Big Leagues Seems like SAGA Metals is making a gutsy move, stepping into some heavy-hitting circles. They just hitched their wagon to the Canadian Chamber of Commerce's Critical Minerals Council. That's not just a foot in the door; that's walking right into the room where national policy gets cooked up. Joining forces here could be their ticket to...

Lifeway Kefir Hits Broadcasters with Football Flair

Kefir Goes Prime Time in Chicago Lifeway Foods, Inc. is stepping up its game with a splashy debut on Chicago's television scene. Just days after announcing the move, the leading player in the kefir industry is rolling out an ad campaign featuring none other than celebrated football stars Colston Loveland and D'Andre Swift. This isn't just any run-of-the-mill commercial...

Tech Job Market Surges with AI and IT Skills Spike

Alright, folks, though we're not drowning in champagne just yet, there's a promising uptick in October's tech employment, signaling a rebound or at least some relief for tech pros and market watchers. CompTIA's numbers show a boost of 7,200 jobs in the tech industry while IT occupations expanded by 26,000 slots. That's no small feat when the general job scene elsewhere...

INOVIO's $75M Offering: A Tough Medicine for Investors

A Shot in the Arm or a Sore Spot? INOVIO Pharmaceuticals is diving headfirst into the capital markets with a $75 million public offering, and let me tell you, the road ahead isn't paved with gold, yet. They've set out to raise funds by pricing 58,747,235 shares at $1.05 a pop, which might have you scratching your head if you're holding INO shares already. Breaking Down...

Reliving the Legacy of Friendship at Friends & Co

Reconnecting With History In an era dominated by fleeting digital interactions, the heartening effort by Friends & Co stands out. This nonprofit is digging back into its roots and asking folks to share tales of the deep bonds formed over the past fifty years under its former guise, Little Brothers – Friends of the Elderly Twin Cities. The mission? To celebrate...

Trucordia Expands BYU Sponsorship with Helmet Branding

Trucordia Gets Visible with BYU Football Alright, BYU fans and insurance buffs, here's your latest play-by-play. Trucordia, a major player in the insurance game, is ratcheting up its visibility in the college sports scene. They've struck gold with a multiyear sponsorship deal putting their logo on Brigham Young University's (BYU) football helmet bumpers. Talk about a...

Dr. Lachlan Forrow Honored with ASF Lifetime Achievement Award

Championing a Legacy of Compassion in Medicine Listen up: not every day you hear about someone leading healthcare with a soul. Here's Dr. Lachlan Forrow, celebrated by the Albert Schweitzer Fellowship for shaping bioethics and medical humanism for over forty years. This fella's carved out a niche that melds heart with healthcare, and that's why he's scoring the inaugural...